Drug
Rolapitant clinical trials
Also written Varubi and SCH 619734.
- studies test it
- 10
- open now
- 0
- in phase 3
- 3
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2012 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Tesaro, Inc. (5) · Duke University (1) · Merck Sharp & Dohme LLC (1) · Schering-Plough (1) · M.D. Anderson Cancer Center (1) · Costantine Albany (1)
Often tested with
Tested in the same studies.
Ondansetron (1) · Palonosetron (1) · Olanzapine (1) · Dexamethasone (1)
Studies
Open first, then newest update. How each study uses rolapitant is read from its arms, and is right about nine times in ten.
Testing it · 10
- Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and TemozolomideCompletedPhase 2Duke UniversityNCT02991456Written as Rolapitant
- Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving ChemotherapyTerminatedPhase 2M.D. Anderson Cancer CenterNCT02732015Written as Rolapitant Hydrochloride
- Rolapitant Plus Olanzapine in Multiday Cisplatin ChemotherapyWithdrawnPhase 2Costantine AlbanyNCT03960151Written as Rolapitant
- Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedPhase 3Tesaro, Inc.NCT01499849Written as Rolapitant
- Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyCompletedPhase 3Tesaro, Inc.NCT01500226Written as Rolapitant
- Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic ChemotherapyCompletedPhase 3Tesaro, Inc.NCT01500213Written as Rolapitant
- A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy VolunteersCompletedPhase 1Tesaro, Inc.NCT02382666Written as Rolapitant
- An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous RolapitantCompletedPhase 1Tesaro, Inc.NCT02285647Written as Rolapitant - Oral
- Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)CompletedPhase 2Merck Sharp & Dohme LLCNCT00506545Written as SCH 619734
- A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)CompletedPhase 2Schering-PloughNCT00394966Written as SCH 619734 Dose 1
Given in every arm · 1 — rolapitant is usual care beside what is tested
Codes
What other systems call rolapitant · ClinicalTrials.gg INT006243
- MeSH (NLM) C578834rolapitantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) NLE429IZUCROLAPITANTConfirmed FDA, NLM, Wikidata
- RxNorm 1665496Confirmed FDA, Wikidata
- Wikidata Q76415423rolapitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97952RolapitantOne source FDA
- DrugBank DB09291One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C578834 | rolapitant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | NLE429IZUC | ROLAPITANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1665496 | — | Confirmed FDA, Wikidata |
| Wikidata | Q76415423 | rolapitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97952 | Rolapitant | One source FDA |
| DrugBank | DB09291 | — | One source Wikidata |
Also registered as rolapitant hydrochloride (UNII 57O5S1QSAQ · RxNorm 1673367).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.